Forest Laboratories reports positive Nebivolol trial results

Forest Laboratories has announced positive trial results of clinical studies and analysis of nebivolol, a compound currently being reviewed by regulatory bodies in the US as a potential treatment for hypertension.

Nebivolol is a selective beta 1-adregenic receptor antagonist – a beta blocker – with vasodilating properties that is currently approved as a hypertension treatment in 50 countries.

The clinical studies showed the efficacy of nebivolol as a treatment for lowering blood pressure in the long term as a monotherapy or in combination with other agents as a treatment for hypertension.

Pooled analysis of other trials presented alongside this study data at the annual meeting of the American Society of Hypertension showed the compound to be an effective monotherapy to treat this condition in obese patients.

Neil Shusterman , senior vice-president of clinical development at ForestResearch Institute, said: “These study results are promising and add to the growing body of data that support nebivolol as a useful treatment for hypertension across a broad population of patients.”

He added that the company feels that the compound will offer a unique treatment option for patients and doctors to manage high blood pressure.

At the start of this month, Forest Laboratories reported that its partners, Mylan Laboratories, had submitted a response to the approval letter for nebivolol received from the US Food and Drug Administration.